Absence of HTLV-I and HTLV-II Proviral Genome in the Brains of Patients with Multiple Sclerosis and Amyotrophic Lateral Sclerosis

G.A. Dekaban, A.J. Hudson and G.P.A. Rice

ABSTRACT: Previous studies have failed to provide serological evidence to incriminate a retroviral infection in the cause of multiple sclerosis. Gene amplification techniques have also failed to identify retroviral footprints in DNA from peripheral blood leukocytes. Here we provide evidence that proviral DNA of HTLV-I and HTLV-II is not found in the central nervous system tissues of patients with multiple sclerosis, patients with amyotrophic lateral sclerosis and controls.

RéSUMÉ: Absence du génome proviral du HTLV-1 et du HTLV-2 dans le cerveau de patients atteints de sclérose en plaques et de sclérose latérale amyotrophique. Des études antérieures n'ont pas montré de manifestations sérologiques impliquant une infection rétrovirale comme cause de la sclérose en plaques. Les techniques d'amplification génique n'ont pas identifié d'empreinte rétrovirale dans l'ADN de leucocytes du sang périphérique. Dans cet article, nous démontrons que l'ADN proviral de HTLV-1 et de HTLV-2 ne se retrouve pas dans les tissus du système nerveux central de patients atteints de sclérose en plaques, de sclérose latérale amyotrophique et de contrôles.


In the last decade, retroviruses have been incriminated in the pathogenesis of some major diseases of the nervous system. The encephalopathy caused by HIV-1 and the myelopathy caused by HTLV-1 are prime examples. The first attempts to implicate such agents in MS provided some encouraging hope that retroviruses might be involved, although the pilot observations have not been reproducible (reviewed 1). Some murine models of amyotrophic lateral sclerosis (ALS) have been shown to be caused by a retrovirus which causes a noninflammatory destruction of anterior horn cells.2 These models have raised speculation that a human retrovirus could act similarly in the pathogenesis of ALS.

We have been unable to find any serological evidence for a human retroviral infection in the pathogenesis of multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS).1 With enzyme linked immunoassays or western blot techniques we could not find antibody to HTLV-1 or HIV-1 in patients with MS or ALS. Furthermore, with gene amplification techniques, we were unable to identify unique retroviral sequences in DNA harvested from blood leukocytes.2

It was important to extend these observations for several reasons. In other nervous system diseases, retroviral footprints can be found only at the site of tissue injury. For example, we found that in a patient with the myelopathy associated with HTLV-1 infection, viral genes could be amplified only from pathologically abnormal spinal cord, and not from elsewhere in the neuraxis.4 It has also become apparent that serology is not uniformly positive in patients with AIDS,5 nor in patients with myelopathies caused by HTLV-1.6 A retroviral etiology in these cases has been shown by gene amplification.

We extended our studies to include DNA extracted from brain and spinal cord. We were unable to find retroviral sequences specific to HTLV-I, HTLV-II or HIV in the brains and spinal cords of patients with MS, ALS and a number of patients with other nervous system diseases.

MATERIALS AND METHODS

Cell Lines

The HTLV-II infected Mo B-cell line was obtained from the American Tissue Culture Collection and grown in Iscove’s modified Dulbecco’s medium, supplemented with glutamine, 2.5 mM Hepes, 10% fetal calf serum, penicillin and streptomycin.
Source of Neural Tissues

Brains and spinal cords were removed from patients with clinically definite ALS and MS within 24 hours of death. The patients with MS had been followed in the London Regional Multiple Sclerosis Clinic, and the ALS patients were obtained from the Southwestern Ontario ALS Registry. Control material was obtained from patients who had succumbed to Guillain-Barre syndrome, various malignancies or fulminant liver failure.

In the patients with ALS (n = 5) DNA was extracted from frontal and occipital cortex, centrum semiovale and medulla oblongata. The hypoglossal nucleus had been involved clinically in all of these patients and this tissue was included in the sampling. In patients with MS (n = 5) we sampled both plaque and the area surrounding plaques, in addition to the above mentioned areas. At least one plaque and one periplaque region was sampled in each MS patient. DNA extracted from peripheral blood lymphocytes from an individual known to have a myelopathy caused by HTLV-I served as a positive control (fresh, or frozen tissues were unavailable).

Purification of DNA

The method for DNA extraction has been described previously.3 We performed a sham extraction time each time that brain DNA was extracted. In this control, the entire extraction procedure is performed, except for the inclusion of sample DNA. This excludes the possibility of DNA contamination during the extraction procedure.

We also ensured that all DNA extracted was suitable for amplification by testing the ability of DNA to amplify beta-actin primers. Any samples that failed to amplify with the beta-actin primers were further purified by a second extraction with phenol/chloroform or by passage over genomic DNA isolation columns (ASAP, Boehringer Mannheim).

Gene Amplification

We routinely employed the controls outlined by Kwok and Higuchi.7 The primers for HTLV-I gag p24 and pol have been described previously.3,3 The HTLV-II pol primers and probe were synthesized based upon sequence information at the following nucleotide positions: 5' primer - 3824 to 3851, 3' primer - 4280 to 4300; probe - 4190 to 4217, based on published sequence.9 The HTLV-II env primers and probe were constructed as follows: 5' primer - 5602 to 5624; 3' primer - 6020 to 6040, probe - 5912 to 5934. The beta-actin primers were constructed as follows: 5' primer - 1857-1883, 3' primer - 2252 to 2277, all based on published sequence.6

Oligonucleotides were synthesized on an ABI oligonucleotide synthesizer and purified as described previously.3,4 Taq-I DNA polymerase was obtained from Perkin Elmer-Cetus or Promega Biotec. Both gave equivalent results. All amplifications were carried out using the "hot start" approach in which the reactions were brought to 80°C before Taq I polymerase was added. All samples were initially denatured for 4 minutes by heating at 95°C and then amplified for 30 cycles of denaturation at 95°C for 70 seconds, annealing at 55°C for 30 seconds and elongation at 72°C for 90 seconds. After the last cycle a final extension was carried out for 10 minutes at 72°C. The PCR products were analyzed as previously described by agarose electrophoresis and southern blotting.3

RESULTS

We first ascertained that all of the DNA extracted could support the amplification of a cellular housekeeping gene. All of the specimens yielded the expected oligonucleotide fragment with the beta-actin primers. Further we showed that with the sham control there was no introduction of exogenous contaminating sequences, and with the primer control there was no amplification of the priming reagents alone (data not shown).

We then amplified the DNA extracted from the clinical samples for evidence of p24 sequences from the HTLV-I gag gene. We could uniformly demonstrate the appropriate 0.623 kilobase fragment in the HTLV-I infected control. This band was

Figure 1 — Amplification of HTLV-I gag p24 sequences from a representative selection of DNA samples extracted from brains of controls (lanes 1-8), a patient with Guillain-Barré Syndrome (lanes 9-12), patients with MS (lanes 12-26, lane 21 excepted) and patients with ALS (lanes 27-39). Sham DNA extraction controls for samples that precede them are located in lanes 2, 5, 8, 12, 14, 16, 19, 23, 26, 32, 35 and 39. The HTLV-I positive DNA sample extracted from peripheral blood of a patient with HAM/TSP is in lane 21 and 41. Lane 40 contains the water control. Lanes 4, 7, 9, 28, 31, 34 and 38 contain DNA from frontal grey matter. Lanes 3, 6, and 29 contain DNA from the occipital grey matter. Lanes 1 and 11 contain DNA from the frontal white matter. Lane 36 contains DNA from medulla. Lanes 13, 17, 20 and 24 contain DNA from MS plaque areas and lanes 15, 18, 22 and 25 contain DNA from MS periplaque areas. The streak of radioactive signal between lanes 33 and 34 is a hybridization artifact.
uniformly absent in the negative controls and in all of the clinical materials that we studied (Figure 1). Similar results were obtained in the pol primers (not shown).

We also examined the same DNA samples for presence of the HTLV-II env and pol genes. These did not have any known homology with HTLV-I. As shown in Figure 2, we could not amplify HTLV-II env sequences. Similar negative results were obtained for the HTLV-II pol primers.

**DISCUSSION**

Evidence to implicate a retrovirus in the etiology of multiple sclerosis has not been forthcoming. Although some of the first serological and gene amplification reports suggested a role for a virus similar to HTLV-I, the consensus is that these observations are not reproducible. The failure to identify retroviral genes in the tissues of ALS patients is in keeping with the negative serological studies published to date. A virus etiology for ALS is still possible. The most compelling evidence derives from the animal models. The mechanism of anterior cell destruction is complicated in these models, with important virus- and host-determined restricting elements.

The failure to amplify highly conserved sequences from HTLV-I and HTLV-II retroviruses certainly does not eliminate the possibility of some role for a retroviral infection. If a retrovirus is involved, it likely derives from a different family. The experiments described in this report were designed to be highly specific for HTLV-I and II sequences. The conditions would not permit the detection of more distantly related retroviruses. Dropping the stringency would possibly permit the detection of other exogenous retroviral sequences, but would be complicated by false positive detection of partially homologous sequences of endogenous retrovirus or cellular sequences.

**ACKNOWLEDGEMENTS**

GD and GPAR are recipients of Career Development Awards from the Ministry of Health of Ontario. We are grateful for the technical expertise of Elaine King and secretarial assistance of Donna Greer. This research was supported by both the Multiple Sclerosis and Amyotrophic Lateral Sclerosis Societies of Canada.

**REFERENCES**


